Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.
Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes ...
Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the ...
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...
WAYNE, Pa. - Aclaris Therapeutics, Inc. (NASDAQ: NASDAQ:ACRS), a clinical-stage biopharmaceutical company with a market ...
Atopic dermatitis is one of the most common types of eczema. Signs may include inflamed skin, rash, itchiness and excessive dryness. It may also include bumps and swollen skin that may ooze. It ...
Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.
Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...
AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...